Summary

The 7 major congenital adrenal hyperplasia markets reached a value of US$ 23.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 44.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.98% during 2024-2034.

The congenital adrenal hyperplasia market has been comprehensively analyzed in IMARC's new report titled "Congenital Adrenal Hyperplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Congenital adrenal hyperplasia (CAH) refers to a group of genetic diseases that affect the adrenal glands, which are small glands that produce steroid hormones. In most cases, CAH causes a deficiency or absence of certain hormones, such as cortisol and aldosterone, and an excess of others, like androgens. This can lead to various symptoms, including ambiguous genitalia in newborn females, premature puberty in males, and menstrual irregularities as well as infertility in adult females. In some cases, the ailment can also cause hypertension, hypokalemia, fatigue, weakness, dehydration, etc. Diagnosing congenital adrenal hyperplasia typically involves blood tests to measure the levels of various hormones, including cortisol, aldosterone, androgens, etc. In newborns, physical exams may be performed to evaluate the genitalia, as ambiguous genitalia can be an early sign of CAH. Genetic testing is also utilized to identify mutations in the genes that encode the enzymes involved in steroid hormone production. Additionally, numerous imaging tests, such as ultrasound or MRI, may be used to examine the size and structure of the adrenal glands.

The rising cases of mutations in genes that affect the enzymes involved in the production of steroid hormones are primarily driving the congenital adrenal hyperplasia market. Moreover, the widespread adoption of glucocorticoids, including hydrocortisone, prednisone, dexamethasone, etc., to suppress the excess formation of androgens and replace the deficient hormones is acting as another significant growth-inducing factor. Besides this, the inflating demand for gene therapy to correct the underlying genetic defect and restore normal hormone production in the adrenal glands is also creating a positive outlook for the market. Additionally, numerous key players are investing in R&D activities to introduce new formulations of existing drugs, such as hydrocortisone and fludrocortisone, as well as novel medications that target specific aspects of the disease. This, in turn, is augmenting the market growth. Furthermore, the emerging popularity of anti-androgens, including spironolactone and flutamide, which block the action of androgens in the body and help prevent or reverse the development of virilization, is expected to drive the congenital adrenal hyperplasia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the congenital adrenal hyperplasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for congenital adrenal hyperplasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the congenital adrenal hyperplasia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the congenital adrenal hyperplasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the congenital adrenal hyperplasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current congenital adrenal hyperplasia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the congenital adrenal hyperplasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the congenital adrenal hyperplasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the congenital adrenal hyperplasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of congenital adrenal hyperplasia across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of congenital adrenal hyperplasia by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of congenital adrenal hyperplasia by gender across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of congenital adrenal hyperplasia by type across the seven major markets?
How many patients are diagnosed (​2018-2034​) with congenital adrenal hyperplasia across the seven major markets?
What is the size of the congenital adrenal hyperplasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of congenital adrenal hyperplasia?
What will be the growth rate of patients across the seven major markets?

Congenital Adrenal Hyperplasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for congenital adrenal hyperplasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the congenital adrenal hyperplasia market?
What are the key regulatory events related to the congenital adrenal hyperplasia market?
What is the structure of clinical trial landscape by status related to the congenital adrenal hyperplasia market?
What is the structure of clinical trial landscape by phase related to the congenital adrenal hyperplasia market?
What is the structure of clinical trial landscape by route of administration related to the congenital adrenal hyperplasia market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Congenital Adrenal Hyperplasia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Congenital Adrenal Hyperplasia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Congenital Adrenal Hyperplasia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Epidemiology by Type (​2018-2034​)
7.2.6 Diagnosed Cases (​2018-2034​)
7.2.7 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Epidemiology by Type (​2018-2034​)
7.3.6 Diagnosed Cases (​2018-2034​)
7.3.7 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Epidemiology by Type (​2018-2034​)
7.4.6 Diagnosed Cases (​2018-2034​)
7.4.7 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Epidemiology by Type (​2018-2034​)
7.5.6 Diagnosed Cases (​2018-2034​)
7.5.7 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Epidemiology by Type (​2018-2034​)
7.6.6 Diagnosed Cases (​2018-2034​)
7.6.7 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Epidemiology by Type (​2018-2034​)
7.7.6 Diagnosed Cases (​2018-2034​)
7.7.7 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Epidemiology by Type (​2018-2034​)
7.8.6 Diagnosed Cases (​2018-2034​)
7.8.7 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Epidemiology by Type (​2018-2034​)
7.9.6 Diagnosed Cases (​2018-2034​)
7.9.7 Patient Pool/Treated Cases (​2018-2034​)

8 Congenital Adrenal Hyperplasia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Congenital Adrenal Hyperplasia - Unmet Needs

10 Congenital Adrenal Hyperplasia - Key Endpoints of Treatment

11 Congenital Adrenal Hyperplasia - Marketed Products
11.1 List of Congenital Adrenal Hyperplasia Marketed Drugs Across the Top 7 Markets
11.1.1 Efmody (Hydrocortisone) - Diurnal
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Congenital Adrenal Hyperplasia - Pipeline Drugs
12.1 List of Congenital Adrenal Hyperplasia Pipeline Drugs Across the Top 7 Markets
12.1.1 BBP631 - Adrenas Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Crinecerfont - Neurocrine Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LuAG13909 - Lundbeck A/S
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 SPR001 - Spruce Biosciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Congenital Adrenal Hyperplasia - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Congenital Adrenal Hyperplasia – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Congenital Adrenal Hyperplasia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Congenital Adrenal Hyperplasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Congenital Adrenal Hyperplasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Congenital Adrenal Hyperplasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Congenital Adrenal Hyperplasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Congenital Adrenal Hyperplasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Congenital Adrenal Hyperplasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Congenital Adrenal Hyperplasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Congenital Adrenal Hyperplasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Congenital Adrenal Hyperplasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Congenital Adrenal Hyperplasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Congenital Adrenal Hyperplasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Congenital Adrenal Hyperplasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Congenital Adrenal Hyperplasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Congenital Adrenal Hyperplasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Congenital Adrenal Hyperplasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Congenital Adrenal Hyperplasia - Access and Reimbursement Overview

16 Congenital Adrenal Hyperplasia - Recent Events and Inputs From Key Opinion Leaders

17 Congenital Adrenal Hyperplasia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Congenital Adrenal Hyperplasia Market – Strategic Recommendations

19 Appendix